Sevabertinib: FDA Approval Ushers in a New Era for Lung Cancer and Precision Medicine The FDA’s recent approval of sevabertinib signals a profound shift in precision medicine, especially for lung cancer patients with limited options. For the first time, a cancer drug originating from t... academic-industry collaboration Broad Institute cancer drug drug discovery FDA approval HER2 mutation lung cancer precision medicine
CRISPR and AI Are Revolutionizing Ebola Drug Discovery Halting a deadly virus like Ebola may seem impossible without targeting the virus directly. Yet, researchers at the Broad Institute of MIT and Harvard, in partnership with Boston University’s NEIDL, h... Broad Institute CRISPR drug discovery Ebola host factors imaging technology machine learning virus research